Over 12 months, Kyverna Therapeutics, Inc. saw more buying than selling from its insiders — purchases of about $2 million against sales of $293,000.
The largest purchase came from SEIDENBERG BETH C (Director), about $1,000,000.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. On the institutional side, 120 funds reported holding KYTX at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 22, 2025 | SEIDENBERG BETH C | Director | Buy | 133,333 | $7.50 | $1000K | SEC |
| Dec 22, 2025 | Westlake BioPartners Opportunity Fund I, L.P. | 10% Owner | Buy | 133,333 | $7.50 | $1000K | SEC |
| Dec 17, 2025 | Walker Karen Marie | Executive Officer | Sell | 23,998 | $12.20 | $293K | SEC |
| Feb 14, 2024 | Vida Ventures GP III, L.L.C. | 10% Owner | Buy | 252,553 | $22.00 | $5.6M | SEC |
| Feb 14, 2024 | Vida Ventures GP III, L.L.C. | 10% Owner | Buy | 583 | $22.00 | $13K | SEC |
| Feb 14, 2024 | Bain Capital Life Sciences Fund III, L.P. | 10% Owner | Buy | 450,000 | $22.00 | $9.9M | SEC |
| Feb 13, 2024 | GILEAD SCIENCES, INC. | 10% Owner | Buy | 910,000 | $22.00 | $20.0M | SEC |
| Feb 12, 2024 | Northpond Ventures III GP, LLC | Other | Buy | 450,000 | $22.00 | $9.9M | SEC |
In the last 12 months Kyverna Therapeutics, Inc. insiders made open-market purchases worth about $2 million and sales worth about $293,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in KYTX was filed on 2025-12-22.
120 investment managers reported holding KYTX in SEC Form 13F filings for Q2 2026.
No congressional trades in KYTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).